2型糖尿病患者的胰高血糖素样肽-1受体显像
本研究在13例超重至肥胖的2型糖尿病患者中开展68Ga-exendin4 PET/CT检查,优化并简化了胰腺GLP1R显像协议。胰腺摄取高但个体间可变,无自阻断证据;胰腺68Ga-exendin4浓度与年龄负相关,与BMI呈正相关趋势,但总GLP1R含量无此关联。
要点
- 68Ga-exendin4 PET/CT可用于胰腺GLP1R的可重复显像。
- 动态扫描可简化为短静态扫描,提高效率并减少不适。
- 胰腺GLP1R密度与年龄负相关,与BMI正相关趋势。
核心结论
- 68Ga-exendin4 PET/CT优化协议可实现胰腺GLP1R可重复显像,有望用于纵向定量及GLP1激动剂靶点结合研究。
研究设计与样本
- 在13例超重至肥胖的2型糖尿病患者中开展68Ga-exendin4 PET/CT检查,为更大靶点结合研究(NCT03350191)的一部分。
- 开发优化可重复性的扫描协议,目标给药量为0.5 MBq/kg(对应肽量<0.2 µg/kg),包括采血和示踪剂稳定性评估。
- 分割胰腺和腹部器官,并将结合与临床参数进行相关性分析。
主要发现
- 胰腺中68Ga-exendin4摄取高但个体间可变,其他腹部组织未见高摄取。
- 在该协议下,尽管exendin4效力高,未观察到示踪剂对GLP1R的自阻断证据。
- 全动态扫描可简化为短静态扫描,可能提高通量并减少患者不适。
- 胰腺68Ga-exendin4浓度(即GLP1R密度)与年龄呈负相关,与体重指数呈正相关趋势,但胰腺总GLP1R含量无此相关性。
临床怎么用
- 可采用简化的短静态68Ga-exendin4 PET/CT扫描协议进行胰腺GLP1R显像。
- 该显像有望用于纵向监测2型糖尿病发展过程中胰腺GLP1R的变化,以及新型GLP1激动剂的靶点结合研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. The PET radioligand 68Ga-DO3A-VS-exendin4 (68Ga-exendin4) has the potential to enable longitudinal studies of GLP1R in the human pancreas. Methods:68Ga-exendin4 PET/CT examinations were performed on overweight-to-obese individuals with type 2 diabetes (n = 13) as part of a larger target engagement study (NCT03350191). A scanning protocol was developed to optimize reproducibility (target amount of 0.5 MBq/kg [corresponding to peptide amount of <0.2 µg/kg], blood sampling, and tracer stability assessment). The pancreas and abdominal organs were segmented, and binding was correlated with clinical parameters. Results: Uptake of 68Ga-exendin4 in the pancreas, but not in other abdominal tissues, was high but variable between individuals. There was no evidence of self-blocking of GLP1R by the tracer in this protocol, despite the high potency of exendin4. The results showed that a full dynamic scan can be simplified to a short static scan, potentially increasing throughput and reducing patient discomfort. The 68Ga-exendin4 concentration in the pancreas (i.e., GLP1R density) correlated inversely with the age of the individual and tended to correlate positively with body mass index. However, the total GLP1R content in the pancreas did not. Conclusion: In summary, we present an optimized and simplified 68Ga-exendin4 scanning protocol to enable reproducible imaging of GLP1R in the pancreas. 68Ga-exendin4 PET may enable quantification of longitudinal changes in pancreatic GLP1R during the development of type 2 diabetes, as well as target engagement studies of novel glucagonlike peptide-1 agonists.
引用
- Eriksson O, Velikyan I, Haack T, et al. Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes. J Nucl Med. 2021. PMID: 34503957. doi:10.2967/jnumed.121.262506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。